HRP20210486T1 - Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilamin za liječenje primarnih negativnih simptoma shizofrenije - Google Patents

Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilamin za liječenje primarnih negativnih simptoma shizofrenije Download PDF

Info

Publication number
HRP20210486T1
HRP20210486T1 HRP20210486TT HRP20210486T HRP20210486T1 HR P20210486 T1 HRP20210486 T1 HR P20210486T1 HR P20210486T T HRP20210486T T HR P20210486TT HR P20210486 T HRP20210486 T HR P20210486T HR P20210486 T1 HRP20210486 T1 HR P20210486T1
Authority
HR
Croatia
Prior art keywords
dimethylcarbamoyl
piperazin
dichlorophenyl
trans
ethyl
Prior art date
Application number
HRP20210486TT
Other languages
English (en)
Inventor
János György PITTER
Balázs SZATMÁRI
Marc Debelle
György József NÉMETH
István Laszlovszky
Original Assignee
Richter Gedeon Nyrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt. filed Critical Richter Gedeon Nyrt.
Publication of HRP20210486T1 publication Critical patent/HRP20210486T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (2)

1. Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin i / ili njegove farmaceutski prihvatljive soli i / ili hidrati i / ili solvati i / ili polimorfi za uporabu u liječenju primarnih negativnih simptoma shizofrenije.
2. Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin za uporabu prema zahtjevu 1, u obliku trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il] -etil}-N,N-dimetilkarbamoil-cikloheksilamin hidroklorid i / ili njegovi hidrati i / ili solvati i / ili polimorfi.
HRP20210486TT 2012-11-29 2021-03-25 Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilamin za liječenje primarnih negativnih simptoma shizofrenije HRP20210486T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU1200691A HU231227B1 (hu) 2012-11-29 2012-11-29 Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
EP13805597.5A EP2925324B1 (en) 2012-11-29 2013-11-28 Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treating primary negative symptoms of schizophrenia
PCT/IB2013/060465 WO2014083522A1 (en) 2012-11-29 2013-11-28 Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treating negative symptoms of schizophrenia

Publications (1)

Publication Number Publication Date
HRP20210486T1 true HRP20210486T1 (hr) 2021-05-14

Family

ID=70289034

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210486TT HRP20210486T1 (hr) 2012-11-29 2021-03-25 Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilamin za liječenje primarnih negativnih simptoma shizofrenije

Country Status (36)

Country Link
US (1) US20150306094A1 (hr)
EP (2) EP2925324B1 (hr)
JP (2) JP2016501215A (hr)
KR (2) KR20210010955A (hr)
CN (1) CN104812390A (hr)
AP (1) AP2015008448A0 (hr)
AU (1) AU2013350819B9 (hr)
BR (1) BR112015012512A2 (hr)
CA (1) CA2890952A1 (hr)
CL (1) CL2015001468A1 (hr)
CR (1) CR20150244A (hr)
CY (1) CY1123766T1 (hr)
DK (1) DK2925324T3 (hr)
EA (1) EA039245B1 (hr)
ES (1) ES2863052T3 (hr)
GE (1) GEP20186849B (hr)
HK (1) HK1212608A1 (hr)
HR (1) HRP20210486T1 (hr)
HU (2) HU231227B1 (hr)
IL (1) IL238723B (hr)
LT (1) LT2925324T (hr)
MD (2) MD4865C1 (hr)
MX (2) MX2015006677A (hr)
MY (1) MY174663A (hr)
NI (1) NI201500074A (hr)
NZ (1) NZ708295A (hr)
PE (1) PE20151052A1 (hr)
PH (1) PH12015501124B1 (hr)
PL (1) PL2925324T3 (hr)
PT (1) PT2925324T (hr)
RS (1) RS61509B1 (hr)
SG (1) SG11201503672SA (hr)
SI (1) SI2925324T1 (hr)
UA (1) UA123492C2 (hr)
WO (1) WO2014083522A1 (hr)
ZA (1) ZA201503660B (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192507A1 (en) 2008-07-16 2013-08-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
HU231173B1 (hu) * 2016-07-08 2021-06-28 Richter Gedeon Nyrt. Ipari eljárás cariprazine előállítására
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
WO2019016828A1 (en) * 2017-07-15 2019-01-24 Msn Laboratories Private Limited, R&D Center NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N- {4- [2- [4- (2,3-DICHLOROPHENYL) PIPERAZIN-1-YL] ETHYL] CYCLOHEXYL} -N ', N'-DIMETHYLUMED HYDROCHLORIDE AND POLYMORPHS THIS ONE
US20200375983A1 (en) * 2017-12-01 2020-12-03 Aurobindo Pharma Ltd A process for the preparation of cariprazine hydrochloride
WO2020056929A1 (zh) * 2018-09-21 2020-03-26 上海诚妙医药科技有限公司 卡利拉嗪盐酸盐的新晶型及其制备方法及其用途
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11344503B2 (en) 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HU230748B1 (hu) 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
HUP0700369A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
KR20100022955A (ko) * 2007-05-24 2010-03-03 리히터 게데온 닐트. (티오) -카르바모일-시클로헥산 유도체 및 정신분열 치료 방법
WO2010126527A1 (en) 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders

Also Published As

Publication number Publication date
US20150306094A1 (en) 2015-10-29
AP2015008448A0 (en) 2015-05-31
KR102314248B1 (ko) 2021-10-19
KR20150088270A (ko) 2015-07-31
JP2019163240A (ja) 2019-09-26
EA201500575A1 (ru) 2015-09-30
CY1123766T1 (el) 2022-05-27
PE20151052A1 (es) 2015-08-09
JP2016501215A (ja) 2016-01-18
HUE054054T2 (hu) 2021-08-30
PL2925324T3 (pl) 2021-06-28
MD4865C1 (ro) 2024-02-29
GEP20186849B (en) 2018-05-10
HUP1200691A1 (hr) 2014-06-30
MX2015006677A (es) 2015-08-10
EP3653211A1 (en) 2020-05-20
MX2021000342A (es) 2021-04-13
NZ708295A (en) 2020-03-27
CA2890952A1 (en) 2014-06-05
SI2925324T1 (sl) 2021-04-30
ES2863052T3 (es) 2021-10-08
EA039245B1 (ru) 2021-12-22
AU2013350819B9 (en) 2018-06-21
UA123492C2 (uk) 2021-04-14
HK1212608A1 (zh) 2016-06-17
MD20150058A2 (ro) 2015-11-30
PT2925324T (pt) 2021-02-16
IL238723B (en) 2020-02-27
WO2014083522A1 (en) 2014-06-05
PH12015501124A1 (en) 2015-08-03
CR20150244A (es) 2015-06-23
AU2013350819B2 (en) 2018-05-31
NI201500074A (es) 2015-09-18
HU231227B1 (hu) 2022-03-28
EP2925324A1 (en) 2015-10-07
MD4865B1 (ro) 2023-07-31
MD20200089A2 (ro) 2021-05-31
AU2013350819A1 (en) 2015-06-04
EP2925324B1 (en) 2020-12-30
DK2925324T3 (da) 2021-03-01
CN104812390A (zh) 2015-07-29
IL238723A0 (en) 2015-06-30
RS61509B1 (sr) 2021-03-31
ZA201503660B (en) 2016-03-30
SG11201503672SA (en) 2015-06-29
LT2925324T (lt) 2021-02-25
BR112015012512A2 (pt) 2017-07-11
MY174663A (en) 2020-05-05
KR20210010955A (ko) 2021-01-28
PH12015501124B1 (en) 2015-08-03
CL2015001468A1 (es) 2015-08-07

Similar Documents

Publication Publication Date Title
HRP20210486T1 (hr) Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilamin za liječenje primarnih negativnih simptoma shizofrenije
CY1118834T1 (el) Συγχωνευμενες ετεροκυκλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης
CY1119076T1 (el) Αλατα πιπεραζινης ως ανταγωνιστες των d3/d2
BR112014030639A2 (pt) inibidores macrocíclicos de vírus flaviviridae
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
UY35684A (es) Formulación de inhibidores de la tirosina quinasa de bazo (syk)
CL2021000044A1 (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017)
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
MX370970B (es) Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica.
SI2938597T1 (sl) Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h- benzo(d)imidazol-2-amin, njihova priprava in uporaba istega
CY1118886T1 (el) Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης
EA201600032A1 (ru) Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
EP2944310A8 (en) MIF inhibitors for the acute or chronic treatment of pulmonary hypertension
RU2012124822A (ru) Средство для лечения миокардиодистрофии при алкогольной интоксикации